9-ING-41 is a glycogen synthase kinase-3 inhibitor.9-ING-41 (2, 4 μM; 48 hours) decreases neuroblastoma cell viability induces apoptosis[2]. 9-ING-41 (0.1-1 μM) inhibits GSK-3 leading to a decreased expression of the NF-κB target XIAP and significant apoptosis in neuroblastoma cells as shown by PARP cleavage, an apoptosis marker[1]. 9-ING-41 (0.5, 1.0, 1.5, 2.0 μM) inhibits the proliferation rate of all TCL and MCL lines with concentrations as low as 1.0 mM.

A cell-permeable derivative of 6-bromoindirubin that displays selective inhibition of GSK-3 with IC50 of 5 nM.

IM-12 is a novel potent GSK-3β inhibitor with IC50 of 53 nM, significantly increases the β-catenin level and activates canonical Wnt signalling.